Dr. Slawin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9511 Collins Avenue
#1403
Bal Harbour, FL 33154Phone+1 305-809-6920Fax+1 305-675-3972
Summary
- No longer in practice, I manage an investment advisory in early stage biotech named Rapha Capital Management (https://raphacap.com). I’m also the Founder and CEO, Eos SENOLYTIX, Inc. (https://eossenolytix.com) and Deliver Therapeutics, Inc., both located at K2 Bio in Houston, TX, and using advanced technologies in novel ways to develop the first therapeutics to arrest or reverse aging.
Education & Training
- Baylor College of MedicineFellowship, Minimally Invasive Urologic Surgery, 1992 - 1994
- New York Presbyterian Hospital (Columbia Campus)Residency, Urology, 1988 - 1992
- Icahn School of Medicine at Mount SinaiResidency, Surgery, 1986 - 1988
- Columbia University Vagelos College of Physicians and SurgeonsClass of 1986
Certifications & Licensure
- FL State Medical License 2018 - 2025
- NY State Medical License 1986 - 2022
- TX State Medical License 1993 - 2019
Awards, Honors, & Recognition
- F. Brantley Scott, Jr., Award for Innovation and Creativity in Urology. Scott Dept. of Urology, Baylor College of Medicine, 2003
- America's Top Doctors Castle Connolly, 2009-2014
- Top Doctors:SE Texas Castle Connolly, 2013
- Join now to see all
Clinical Trials
- Medical Therapy of Prostatic Symptoms Start of enrollment: 1995 Dec 01
- A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology Start of enrollment: 2012 Aug 01
Publications & Presentations
PubMed
- 64 citationsTwo-Dimensional Regulation of CAR-T Cell Therapy with Orthogonal Switches.My Linh T. Duong, Matthew R. Collinson-Pautz, Eva Morschl, An Lu, Slawomir P. Szymanski
Molecular Therapy Oncolytics. 2019-03-29 - Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies.Matthew R Collinson-Pautz, Wei-Chun Chang, An Lu, Mariam Khalil, Jeannette W Crisostomo
Leukemia. 2019-03-01 - Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies.Matthew R Collinson-Pautz, Wei-Chun Chang, An Lu, Mariam Khalil, Jeannette W Crisostomo
Leukemia. 2019-03-01
Journal Articles
- A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Utility of Tacrolimus (FK506) for the Prevention of Erectile Dysfunction Following Bilateral Nerve-S...John P Mulhall, Eric A Klein, Kevin Slawin, Peter T Scardino, The Journal of Sexual Medicine
Press Mentions
- Rapha Capital Management Launches $100M Life Science VC Fund with an Eye on Early ScienceApril 16th, 2021
- AHA, Children’s Heart Foundation Award Funds to Research in Congenital Heart DefectsFebruary 13th, 2021
- Biopharmaceutical Company AsclepiX Therapeutics Raises $35 MillionJune 29th, 2020
- Join now to see all
Industry Relationships
- Board Member, 3DBio, Inc2019 - Present
- Founder and Managing Partner, Rapha Capital Management, LLC2018 - Present
- Board Member, AsclepiX Therapeutics2018 - Present
- Founder, Bellicum Pharmaceuticals, Inc.2004 - Present
External Links
- Rapha Capital Management LLChttp://raphacap.com
- LinkedInhttp://linkedin.com/in/kevinslawin
- Eos SENOLYTIX https://eossenolytix.com
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: